Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06120842 · ClinicalTrials.gov registry record · Phase 1
Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution
A Phase 1 study of Glaucoma and Cataract, sponsored by SpyGlass Pharma.
- Active
- Registry status
- Phase 1
- Development phase
- 201
- Enrollment target
- 1
- Study location
NCT06120842 is a Phase 1 study of Glaucoma and Cataract that is active but no longer recruiting, run by SpyGlass Pharma. The registered enrollment target is 201 participants, below the 908-participant average among 92 other Glaucoma trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06120842, a Phase 1 study of Glaucoma and Cataract, is active but no longer recruiting, sponsored by SpyGlass Pharma.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 201 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial is a randomized study to evaluate and compare two doses of the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery.
Conditions Studied
Interventions
- DEVICE SpyGlass IOL
- DRUG Timolol Maleate Ophthalmic Solution, 0.5%
- DRUG Bimatoprost Implant System (High Dose)
- DRUG Bimatoprost Implant System (Low Dose)
- DEVICE Commercially Available Aspheric Monofocal Non-Yellow Chromophore IOL
Study Locations (1)
Arizona
- Arizona Advanced Eye Research Institute - Glendale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2023-10-13 |
| Est. Completion | 2027-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06120842
The ClinicalTrials.gov registry entry for NCT06120842 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 201 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 908-participant average among 92 other Glaucoma trials with a reported enrollment target (78% lower). The listed sponsor is SpyGlass Pharma, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Glaucoma appearing as the primary indexed condition, and to 5 interventions - of which SpyGlass IOL is the first listed.
NCT06120842 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT06120842 about?
NCT06120842 is a clinical study titled "Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution". This trial is a randomized study to evaluate and compare two doses of the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery.
What is the current status of trial NCT06120842?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 201 participants. The study started on 2023-10-13. Estimated completion is 2027-11.
What conditions does trial NCT06120842 study?
This clinical trial studies the following conditions: Glaucoma, Cataract, Ocular Hypertension.
What interventions are being tested in trial NCT06120842?
The interventions under investigation include: SpyGlass IOL (DEVICE), Timolol Maleate Ophthalmic Solution, 0.5% (DRUG), Bimatoprost Implant System (High Dose) (DRUG), Bimatoprost Implant System (Low Dose) (DRUG), Commercially Available Aspheric Monofocal Non-Yellow Chromophore IOL (DEVICE).
Who is sponsoring clinical trial NCT06120842?
This trial is sponsored by SpyGlass Pharma, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06120842 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Topical Insulin for Glaucoma
RECRUITING · Phase 1
-
Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.
ACTIVE NOT RECRUITING · Phase 1
-
A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma
COMPLETED · Phase 1
-
Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt
COMPLETED · Phase 1
-
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
COMPLETED · Phase 1
-
Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.